Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

) in late April, InterMune, Roche and Pharmasset, Inc. reported top-line results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients with HCV infection. Data from the first four dosage cohorts of the study were as follows:
  • The combination resulted in sustained viral load reductions over the dosing period in all cohorts. Seventy percent (70%) of patients in the last two dosage cohorts had levels of virus in their blood below the limit of quantification by the diagnostic assay at day 14, and 33% of these patients had no detectable virus in their blood at day 14.
  • Patients receiving the combination of ITMN-191 and R7128 for 14 days experienced a median reduction in viral levels of -4.8 to -5.2 Log10 IU/mL in the last two cohorts tested.
  • In the early low-dose groups, after only three days of dosing, the mean reduction in viral load levels was 0.6 log10 greater with combination treatment (-2.9) compared to the performance of the individual compounds when given as monotherapy (-0.46 and -1.84 for R7128 and R7227, respectively).
  • The combination was well tolerated over 14 days, with no treatment-related serious adverse events (SAEs), dose reductions or discontinuations. Pharmacokinetic analysis confirmed that there were no drug-drug interactions between the compounds.

  • On April 21, InterMune reported that based on these promising early results, the INFORM-1 study had been expanded to explore the interferon-free regimen in treatment-experienced patients; both treatment failures and null-responder HCV patients and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts of
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Nanoparticles, engineered materials about a billionth of a meter ... are tiny, they can benefit human health, as in ... interfere with it through viruses, air pollution, traffic emissions, ... at Washington University in St. Louis, led by Lan ... in Electrical & Systems Engineering, and their collaborators at ...
(Date:9/2/2014)... 2014 Press attending the Project LIBERTY ... advantage of the people and events in Emmetsburg on ... available throughout the day. Additionally, we will do our ... DSM representatives as well as representatives from the local ... , Please remember to RSVP to Matt Merritt ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... (Nasdaq: NTII ), today announced that Paul E. ... Rodman & Renshaw,10th Annual Healthcare Conference November 10 to ... presentation will take place at 3:15 p.m. (ET) on,November ... be accessed by going to:, http://investor.shareholder.com/ntii/events.cfm , ...
... of $0.73, up 192% from third quarter 2007, - New business ... business authorizations of $1 billion at Sept. 30, 2008, up 16% ... from Dec. ... global full-service clinical research organization, today reported,record net income of $11.0 million or ...
... 67% from Same Prior Year Period, DUBLIN, Calif., ... pharmaceutical company dedicated to the discovery and,development of novel ... and nine months ended September 30, 2008., Total ... compared,with $6.1 million for the same prior year period. ...
Cached Biology Technology:Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 3Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 4Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 5Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 7Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 8SuperGen Reports 2008 Third Quarter Financial Results 2SuperGen Reports 2008 Third Quarter Financial Results 3SuperGen Reports 2008 Third Quarter Financial Results 4SuperGen Reports 2008 Third Quarter Financial Results 5SuperGen Reports 2008 Third Quarter Financial Results 6SuperGen Reports 2008 Third Quarter Financial Results 7SuperGen Reports 2008 Third Quarter Financial Results 8SuperGen Reports 2008 Third Quarter Financial Results 9SuperGen Reports 2008 Third Quarter Financial Results 10
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... In Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone ... discoveries of emblematic fossils from that area (for ... have found fossil insects in the French equivalent ... new species representing the oldest known water treader. ... equivalent Bavarian outcrops, fewer fossils have been obtained ...
(Date:9/2/2014)... stress in stride; others are done in by it. ... mechanisms of this so-called stress gap in mice with ... lead researchers to better understand the development of psychiatric ... each animal has unique experiences as it goes through ... can alter the expression of genes, and as a ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... of the human genetic code to determine why some people,s blood ... Johns Hopkins and in Boston have found a septet of overactive ... results give us a clear set of new molecular targets, the ... us identify people more at risk for blood clots and for ...
... A protein whose primary role is in the ... role in treating kidney failure. Indiana University ... kidney injury in laboratory experiments using cells that ... research suggests there could be a potential future ...
... In August of 2008 Jacob Schaefer, PhD, on vacation in San ... As it happened, the newspaper was running a series on the ... are more frequent they now occur every few years instead ... The more intense fire cycle is fueled by cheatgrass (Bromus ...
Cached Biology News:Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3Genetically modified cell procedure may prove useful in treating kidney failure 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 3In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 4In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 5
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
... EnzoLyte MG Phosphate Assay Kit is ... formed between Malachite Green, molybdate and free ... reaction can be conveniently measured on a ... reader. The non-radioactive colorimetric assay kits have ...
... of digital x-ray detectors from KUBTEC represents ... with 12 to 16 bit digital interface. ... photodiode array sensor with pixel spacing down ... in low x-ray energies (10-50 kV) and ...
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
Biology Products: